Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

November 27, 2019November 27, 2019

Liminal Biosciences’s PBI-4050 Reduces Pulmonary Hypertension, Preclinical Data Show

News, PH News

New preclinical data supports the positive effects of Liminal Biosciences’s lead candidate, PBI-4050, in reducing pulmonary hypertension and the abnormal enlargement of the heart’s right ventricle muscle. The company presented its ... Read more

November 6, 2019November 6, 2019

Prerequisite Response Achieved in 83% of Patients After Levosimendan Infusion in HELP Trial

News, PH News

Fifteen out of 18 patients (83%) enrolled in the Phase 2 HELP study testing levosimendan achieved the predefined response required in the open-label phase of the study, Tenax Therapeutics announced. The investigational therapy ... Read more

October 25, 2019October 25, 2019

Rodatristat Ethyl May Reduce Serotonin Production and Affect Vascular Remodeling in PAH Patients, Study Suggests

News, PAH News

Oral treatment with rodatristat ethyl is safe and reduced the levels of serotonin — a hormone whose high levels may promote the tightening of pulmonary artery muscle cells — ... Read more

October 23, 2019October 23, 2019

Opsumit-Adcirca Combo Improves Blood Flow and Physical Capacity in People New to PAH, Trial Data Show

News

A combination of Opsumit (macitentan) plus Adcirca (tadalafil) lowered pulmonary vascular resistance — a measure showing how well blood flows through vessels — by 47% in people newly diagnosed with pulmonary arterial ... Read more

October 9, 2019October 9, 2019

Low Blood Levels of Secretin Hormone May Trigger PH, Mouse Study Suggests

News, PH News

Loss of a hormone called secretin (SCT) induces hypertension, scarring, and structural alterations in the heart and lungs, a study in mice reports. The study “Loss of secretin results ... Read more

October 4, 2019October 4, 2019

Halting Slug Protein May Lessen Risk of PH in Fibrotic Lungs, Study Suggests

News

Halting a protein called Slug may help reduce the severity of increased blood pressure related to lung scarring — a condition called pulmonary hypertension (PH) secondary to pulmonary fibrosis, ... Read more

August 1, 2019August 2, 2019

Adempas May Improve Endothelial Cells’ Function in CTEPH, Study Suggests

CTEPH News, News

The vasodilator Adempas (riociguat) increases the ability of endothelial progenitor cells to halt vascular remodeling and enhance formation of new blood vessels in chronic thromboembolic pulmonary hypertension (CTEPH), according to a new ... Read more

July 17, 2019July 17, 2019

Raising Levels of Nur77 May Help Halt Progression of PH, Study Suggests

News, PAH News, PH News

Increasing levels of the receptor Nur77 in cells lining the blood vessels of patients with pulmonary hypertension (PH) may help halt progression of the disease by enhancing the signaling ... Read more

July 10, 2019July 10, 2019

TAVI Heart Valve Surgery Has Fewer Complications for PH Patients, Analysis Shows

News

In patients with pulmonary hypertension (PH) with aortic stenosis — when the heart’s aortic valve fails to properly close/open — undergoing a transcatheter aortic valve implantation (TAVI) surgical procedure ... Read more

June 17, 2019June 17, 2019

Opsumit Shows Promise for Portopulmonary Hypertension in Phase 4 Trial

News, PAH News

Treatment for 12 weeks with Actelion Pharmaceuticals’ Opsumit (macitentan) significantly improved blood vessels’ resistance in patients with portopulmonary hypertension without causing further damage to the liver, data from the PORTICO ... Read more

Pin It on Pinterest